on August 14, 2003
Published online before print August 14, 2003, doi: 10.1161/01.ATV.0000090673.96120.67
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 19, 2003
Accepted on July 28, 2003
Chondroitin Sulfate Anticoagulant Activity Is Linked to Water Transfer. Relevance to Proteoglycan Structure in Atherosclerosis
Maria McGee * and William D. Wagner
From the Department of Internal Medicine (M.M.) and Department of Pathology (W.D.W.), Wake Forest University School of Medicine, Winston-Salem, NC.
* To whom correspondence should be addressed. E-mail: mmcgee{at}wfubmc.edu.
Objective--Changes in chondroitin sulfate (CS) proteoglycan (PG) during atherosclerosis are associated with chronic inflammatory changes and increased incidence of thrombosis. To explore how glycosaminoglycan changes could influence the thrombogenicity of atherosclerotic lesions, water-transfer reactions were examined during activation of antithrombin by CS.
Methods and Results--Advanced type IV atherosclerotic lesions prone to thrombosis contained CSPG (versican) with undersulfated CS relative to CS of the adjacent healthy aorta. Approximately 11% of the CS disaccharide in versican from healthy arteries was oversulfated, but this proportion decreased markedly to 3% in atherosclerotic lesions. Oversulfated CS functionally bound antithrombin with a dissociation constant of 3.3±1.9 µmol/L. Measured by osmotic stress (OS) techniques with an 
26-Å probe, the reaction was linked to transfer of 2500 mol water per mole of coagulation factor Xa inhibited. Under OS, the anticoagulant efficiency of CS was 1.3 (µmol/L)-1 · s-1, 5- and 15-fold higher than heparan sulfate efficiency measured under OS and standard conditions, respectively.
Conclusions--Decreased sulfation of high molecular weight CSPG in the advancing atherosclerotic lesions may predispose the lesions to thrombosis by disrupting osmotic regulation, limiting avidity for antithrombin and decreasing activation efficiency.
Key words: atherosclerosis • osmotic stress • antithrombin • chondroitin sulfate proteoglycan • coagulation
This article has been cited by other articles:
 |
|
 |
|
  A. L. Myers, V. V. Upreti, M. Khurana, and N. D. Eddington Characterization of Total Plasma Glycosaminoglycan Levels in Healthy Volunteers Following Oral Administration of a Novel Antithrombotic Odiparcil With Aspirin or Enoxaparin J. Clin. Pharmacol., October 1, 2008; 48(10): 1158 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-S. Zheng, M. Reis, C. Sparling, D. Y. Lee, D. P. La Pierre, C.-K. A. Wong, Z. Deng, S. Kahai, J. Wen, and B. B. Yang Versican G3 Domain Promotes Blood Coagulation through Suppressing the Activity of Tissue Factor Pathway Inhibitor-1 J. Biol. Chem., March 24, 2006; 281(12): 8175 - 8182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Pineda, C. J. Carrell, L. A. Bush, S. Prasad, S. Caccia, Z.-W. Chen, F. S. Mathews, and E. Di Cera Molecular Dissection of Na+ Binding to Thrombin J. Biol. Chem., July 23, 2004; 279(30): 31842 - 31853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Wight and M. J. Merrilees Proteoglycans in Atherosclerosis and Restenosis: Key Roles for Versican Circ. Res., May 14, 2004; 94(9): 1158 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Di Cera Atherosclerosis: Testing the Water Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1713 - 1714. [Full Text] [PDF]
|
|